AstraZeneca’s Tagrisso Chemo Combo Impresses But Not A Gamechanger
Reduces Risk Of Lung Cancer Progression By 38%
The detailed results from FLAURA2 have provided a boost for AstraZeneca's Tagrisso franchise, although the combination of the drug plus chemotherapy is unlikely to challenge the convenience that the company's biggest earner already offers for most patients.
You may also be interested in...
Improvements in PFS compared to chemotherapy may help broaden Rybrevant’s indication in EGFR-mutated non-small cell lunger cancer. Investors await data from a head-to-head trial testing it versus AstraZeneca’s Tagrisso.
A Phase III trial of Rybrevant with lazertinib versus Tagrisso in first line EGFR-positive NSCLC is continuing after an interim analysis, surprising some investors who thought it might be stopped early for efficacy.
The Boston-based biotech is weighing up its options as the fall-out from its failed IPF candidate casts a shadow over Galecto’s future.